Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Debt / NOTE 1.500%10/1
-
Number of holders
-
31
-
Total 13F principal, excl. options
-
357,830,003
-
Principal change
-
+59,235,281
-
Total reported value, excl. options
-
$356,597,732
-
Value change
-
+$39,494,990
-
Number of buys
-
14
-
Number of sells
-
-24
-
Price
-
$1.00
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 as of Q3 2020
46 filings reported holding 09061GAF8 - BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 as of Q3 2020.
BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 has 31 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $357,830,003 of principal
.
Largest 10 bondholders include Weiss Asset Management LP ($65,841,000 of principal), D. E. Shaw & Co., Inc. ($60,985,000 of principal), Kohlberg Kravis Roberts & Co. L.P. ($40,182,000 of principal), Invesco Ltd. ($32,780,000 of principal), FRANKLIN RESOURCES INC ($29,700,000 of principal), TENOR CAPITAL MANAGEMENT Co., L.P. ($29,597,000 of principal), JPMORGAN CHASE & CO ($16,879,000 of principal), Sculptor Capital LP ($15,000,000 of principal), OAKTREE CAPITAL MANAGEMENT LP ($13,428,000 of principal), and LAZARD ASSET MANAGEMENT LLC ($10,982,000 of principal).
This table shows the top 31 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.